Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exhaled breath analysis to predict response to mepolizumab in adults with severe asthma
NL-OMON26797Recruiting
- Sponsor
- University of Amsterdam
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of mepolizumab in asthma and eosinophilic asthma (EA), sponsored by University of Amsterdam. Primary endpoint: eNose breathprints. Started Jan 2016; status: recruiting.
02
Drugs
mepolizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON26797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26797.